COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|
Oct. 22, 2025 |
Jan. 21, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Dec. 19, 2025 |
|
| Loss Contingencies [Line Items] | |||||
| Price per share | $ 10.00 | ||||
| Deferred legal fees | $ 3,085,000 | $ 2,450,000 | |||
| Note Receivable [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Principal amount | $ 300,000 | ||||
| Non-refundable fee | $ 10,000 | ||||
| Debt instrument description | (i) June 30, 2026 (as extended), (ii) the date upon which all or any part of the obligations have been declared or automatically have become due and payable (whether by acceleration or otherwise); and (iii) the date upon which the Proposed Business Combination (as defined below) between the Borrower and the Lender or any third-party bridge financing, outside financing or similar capital-raising transaction by the Borrower is consummated. The obligations may be prepaid at any time without penalty. | ||||
| Maturity date | Jun. 30, 2026 | ||||
| Periodic payment | $ 300,000 | 300,000 | |||
| ONE Nuclear Energy LLC, [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Business combination, description | The number of shares to be issued at the Closing will be calculated by dividing $1.00 billion by an amount equal to the price at which each HVII Public Share may be redeemed in connection with the Proposed Business Combination. | ||||
| General Matters [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Deferred legal fees | 2,485,000 | $ 1,850,000 | |||
| Maximum [Member] | Note Receivable [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Principal amount | 300,000 | ||||
| Underwriting Agreement [Member] | Maximum [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Deferred underwriting discount per unit | $ 0.40 | ||||
| Deferred underwriting commissions | $ 7,600,000 | ||||
| IPO [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Sale of units in initial public offering | 19,000,000 | ||||
| Deferred legal fees | $ 600,000 | ||||
| IPO [Member] | Underwriting Agreement [Member] | |||||
| Loss Contingencies [Line Items] | |||||
| Sale of units in initial public offering | 1,500,000 | 2,625,000 | |||
| Remaining unexercised balance | 1,125,000 | 1,125,000 | |||
| Price per share | $ 0.20 | ||||
| Cash underwriting discount | $ 3,800,000 |
| X | ||||||||||
- Definition Cash underwriting discount. No definition available.
|
| X | ||||||||||
- Definition Deferred underwriter commission noncurrent. No definition available.
|
| X | ||||||||||
- Definition Deferred underwriting discount per unit No definition available.
|
| X | ||||||||||
- Definition Non-refundable fee. No definition available.
|
| X | ||||||||||
- Definition Description of acquiree in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Face (par) amount of debt instrument at time of issuance. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the required periodic payments including both interest and principal payments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. No definition available.
|
| X | ||||||||||
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
| X | ||||||||||
- Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|